Introduction
With 841,080 new cases and 781,631 deaths annually, hepatocellular carcinoma (HCC) ranks the sixth most commonly diagnosed malignancy and the fourth leading cause of death worldwide [
1]. Despite great efforts dedicated in the therapeutic strategies for HCC over the past years, including surgical resection, liver transplantation, and comprehensive therapy, the 5-year survival rate of HCC patients remains dismal. Therefore, elucidating the molecular mechanisms underlying HCC and determining novel molecular targets are essential to develop effective treatment modalities for this deadly malignancy.
Long non-coding RNAs (lncRNAs), a class of functional non-coding RNA transcripts > 200 nt in length, are engaged in diverse biological processes across every branch of life. Specific patterns of lncRNA expression coordinate cell differentiation, development, and pathogenesis. It has been widely recognized that many lncRNAs are dysregulated and play an important part in cancer progression [
2]. In HCC, lncRNAs have been reported to affect various malignant phenotypes, such as cell proliferation, motility, and glucose metabolism reprogramming [
3‐
5]. However, investigations of the involvement of lncRNAs in aberrant lipid metabolism in HCC are few. LncRNA-NEAT1 disrupts lipolytic enzyme ATGL-mediated lipolysis and drive HCC proliferation by binding miR-124-3p [
6]. LncRNA HULC activates the acyl-CoA synthetase subunit ACSL1 in a miR-9-dependent manner to promote lipogenesis and function as an oncogene in hepatoma cells [
7].
Long non-coding RNA 00958 (LINC00958) is originally identified as an oncogenic gene in bladder cancer by Seitz et al. [
8]. Subsequent studies demonstrated that LINC00958 is upregulated in several other malignancies, including glioma [
9], oral [
10], gastric [
11], pancreatic [
12], and gynecological cancer [
13,
14]. The involvement of LINC00958 in HCC has not yet been documented, prompting us to explore its biological functions and clinical value.
Polymeric nanoparticle (NP) platforms are emerged as promising carriers in cancer therapy by delivering a variety of drugs, including small interfering RNAs (siRNAs). NPs prevent siRNAs from rapid degradation, increase the drug concentration at tumor sites, and enable sustained release [
15]. NPs formulated with poly(lactic acid/glycolic) (PLGA) copolymer are particularly attractive for clinical applications, due to their low immunogenicity, non-toxicity, biocompatibility, and biodegradability [
16]. Poly(ethylene glycol) (PEG) is safe for clinical application and has been used in many Food and Drug Administration-approved medications including intravenous injections [
17]. PEGylated PLGA NPs have been acknowledged as one of the best controlled release nanoplatforms for targeted drug delivery [
18].
In the current study, we showed that LINC00958 was a lipogenesis-associated lncRNA that exacerbated HCC malignant phenotypes and independently predicted patient survival outcomes. Patient-derived xenograft (PDX) mouse models were adopted to evaluate the tumor-promoting role of LINC00958 in vivo. Mechanistically, METTL3-mediated N6-methyladenosine (m6A) induced the upregulation of LINC00958, which subsequently promoted HCC progression through the miR-3619-5p/HDGF axis. We developed a novel PLGA-based si-LINC00958 nanoplatform and evaluated its superiority for the treatment of HCC.
Materials and methods
Patients and tissue samples
Fresh tumor tissues and paired adjacent non-tumor samples were collected from 80 HCC patients who underwent surgical resection from January 2012 to December 2014 in the First Affiliated Hospital of Nanjing Medical University. The tissue samples were preserved in liquid nitrogen. All patients did not receive preoperative chemotherapy or radiotherapy and signed the written informed consents. This study was approved by the ethical review board of the First Affiliated Hospital of Nanjing Medical University.
Fluorescence in situ hybridization (FISH)
Specific FISH probes to LINC00958 and miR-3619-5p were designed and synthesized by Servicebio (Wuhan, China). The hybridization was performed in HCC cells and tissues as previously reported [
19]. All images were analyzed on a confocal laser scanning microscope (Leica Microsystems, Mannheim, Germany). The FISH probe sequences are shown as follows: LINC00958: 5′-TCCTCCCATGTTTTTGTCTTCCCTACCACC-3′; miR-3619-5p: 5′-GCTGCACCAGCCTGCCTGCTGA-3′.
Lentivirus transfection and stable cell line construction
We purchased lentivirus overexpressing LINC00958 or HDGF, and small hairpin RNA (shRNA) targeting LINC00958 or METTL3 from Genechem (Shanghai, China). Lentiviruses were transfected into HCC cells with 5 mg/ml polybrene for 48 h. Stable cell clones were selected for 1 week using puromycin (5 μg/ml). The overexpression or knockdown efficiency was detected by RT-qPCR. The sequences used are provided as follows: sh1-LINC00958: 5′-GTACCCAAGTTATTCAGGATT-3′, sh2-LINC00958: 5′-GTGACTAGCTTAAACTAAATT-3′, sh3-LINC00958: 5′-GAGGTACCCAATAGTTTCATT-3′; sh-METTL3: 5′-GCCAAGGAACAATCCATTGTT-3′.
RNA immunoprecipitation (RIP)
RIP assay was performed using a Magna RIP RNA-binding Protein Immunoprecipitation Kit (Millipore, Bedford, MA, USA) in accordance with the manufacturer’s protocol. Cells were isolated and lysed by RIP lysis buffer and incubated with antibodies against AGO2 (Abcam, Cambridge, MA, USA), or m6A (Synaptic Systems, Goettingen, German) at 4 °C overnight. IgG was used as negative control. The immunoprecipitated RNAs were eluted and analyzed by RT-qPCR.
Biotin-labeled miRNA pull-down assay
Cells lysates were harvested 48 h after transfecting with 50 nM of biotin-labeled miRNAs (GeneCreate, Wuhan, China). Streptavidin-coupled Dynabeads (Invitrogen) were washed and resuspended in the buffer. Then an equal volume of the biotin-labeled miRNAs was added in the buffer. After incubating at room temperature for 10 min, the coated beads were separated with a magnet for 2 min and washed three times. The isolated RNAs were then subjected to RT-qPCR analysis.
RNA sequencing
Total RNA was isolated from sh-NC (n = 3) and sh-LINC00958 (n = 3) HCCLM3 cells. RNA samples were analyzed by RNA sequencing (BGI, Shenzhen, China) based on the manufacturer’s protocols. Briefly, BGISEQ-500 platform was used to sequence the samples for subsequent generation of raw data. Genes significantly differentially expressed between sh-NC and sh-LINC00958 cells were selected based on fold change ≥ 2.0 and P ≤ 0.001 using the DEGseq method. Functional pathway analysis was conducted using KEGG pathway enrichment analysis.
Oil Red O staining
HCC cells were fixed in 4% paraformaldehyde for 20 min and then permeabilized in 60% isopropanol for 10 s. Subsequently, cells were stained with Oil Red O working solution for 30 min at room temperature, washed three times with PBS, and photographed under a microscope. Oil Red O staining in frozen sections of HCC tissues were similarly performed.
PDX mouse model
NOD/SCID and BALB/c mice were used for the establishment of the HCC PDX model. Briefly, we collected the primary HCC tissues from two patients after surgical resection and kept the specimens in iced culture medium supplemented with 1% penicillin/streptomycin. Then, the tissues were diced into 2–3-mm3 pieces and subcutaneously implanted into the flanks of NOD/SCID mice. When the xenografted tumors grew up to 1–2 cm3, we harvested the tissues from the mice bearing PDX tumors and cut the tissues into pieces. The tumor fragments were further implanted into BALB/c nude mice for the serial transplantation. When the tumor volume reached 50 mm3, we intratumorally injected recombinant lentivirus vectors into tumor tissues continuously for 20 days. Tumor weight and volume were recorded.
Preparation of PLGA-PEG(si-LINC00958) NPs
We used the double emulsion solvent diffusion method for NP preparation as previously described [
20]. si-LINC00958 was reconstituted in DEPC water and then mixed with spermidine (Sigma-Aldrich) at the N/P ratio (the ratio of polyamine amine groups to siRNA phosphate groups) of 8:1. The resultant mixture was incubated for 15 min at room temperature to form si-LINC00958/spermidine complex. PLGA-PEG-COOH (10 mg; DaiGang Biomaterial Co. Ltd., Jinan, China) was dissolved in 500 μl of dichloromethane (Aladdin Industrial Corp., Shanghai, China). Then, the above dichloromethane solution was added dropwise to si-LINC00958/spermidine complex with a probe sonicator (VCX 130; Sonics & Materials, Inc., Newtown, CT, USA) in an ice bath. The resultant primary emulsion was further added dropwise to 4 ml of an aqueous phase containing 2.5% polyvinyl alcohol (Aladdin Industrial Corp.) and emulsified using probe sonication for 1 min. The second emulsion was then stirred at room temperature for 4 h to evaporate the organic solvent. Subsequently, the NPs were collected by centrifugation for 15 min and washed twice with DEPC water.
We used dynamic light scattering (DLS) with a Nano Particle Analyzer (Zetasizer Nano ZSE, Malvern Instruments Ltd., UK) to investigate the size, zeta potential, and polydispersity index (PDI) of the NPs. A drop of the sample was placed onto a copper mesh and dried in room temperature to obtain transmission electron microscopy (TEM) images of the NPs. The siRNA encapsulated in PLGA was measured using UV spectrophotometry to determine the encapsulation efficiency as previously described [
21].
In vivo antitumor efficacy and toxicity evaluation of NPs
To investigate the suppressive effect of PLGA-PEG(si-LINC00958) NPs on HCC cell growth in vivo, PDX tumor models were created as described above. When the tumors developed to 50 mm3, PLGA-PEG(si-LINC00958) NPs or PLGA-PEG(siRNA control) NPs at a dose of 200 mg/kg were injected into the mice (n = 14 in each group) through the tail vein twice weekly. Treatment continued until 4 weeks later, at which point four mice in each group were sacrificed. Tumor weight and volume were recorded immediately. Tumors were subjected to subsequent RT-qPCR and western blotting analyses. The major organs, including the liver, kidney, lung, spleen, and heart, were harvested and fixed with 4% paraformaldehyde for further hematoxylin-eosin (H&E) examination. Blood alanine transaminase (ALT), aspartate transaminase (AST), creatinine (Cr), and blood urea nitrogen (BUN) were also analyzed. The remaining ten mice in each group were monitored for survival analysis with 10 weeks as the cutoff.
Statistical analysis
SPSS 24.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA) were used to perform the statistical analysis. Data are shown as mean ± SEM of the mean. Two-sided Student’s t test was used to analyze the differences between groups. The differences of LINC00958 and HDGF expression levels between tumor and non-tumor specimens were evaluated by paired t test. Chi-square test was adopted to analyze the association of LINC00958 and METTL3 expression with clinicopathological features. Kaplan-Meier curve with log-rank test was used to compare the survival outcome, and Cox proportional hazards model was employed for multivariate survival analysis. Pearson’s correlation was performed to analyze the correlation between LINC00958, miR-3619-5p, METTL3, and HDGF levels. P value less than 0.05 was considered statistically significant.
Supplementary methods are described in Additional file
1.
Discussion
LncRNAs have been established as crucial regulators in pathogenesis, especially in malignancies [
32]. In the present study, we used TCGA data to determine a landscape of differentially expressed lncRNAs in HCC, which revealed a significant upregulation of LINC00958 in HCC. We then confirmed that LINC00958 was highly expressed in HCC by RT-qPCR and FISH assays. High LINC00958 level was correlated with multiple malignant clinicopathological characteristics and was an independent predictor for unfavorable survival outcome. By loss-of-function and gain-of-function experiments, we demonstrated that LINC00958 promoted the proliferation, migration, and invasion of HCC in vitro. PDX models have emerged as invaluable preclinical models for cancer research [
33]. We adopted PDX models and verified the tumor-promoting role of LINC00958 in vivo. Sequestration of miRNAs is the most frequently reported mechanism by which lncRNAs exert their regulatory function. Given the cytoplastic distribution of LINC00958 in HCC, we wondered whether LINC00958 could serve as a miRNA sponge. We screened six miRNAs overlapped by two different bioinformatics databases and verified the binding between LINC00958 and miR-3619-5p using RIP, dual luciferase reporter, RNA pull-down, and FISH assays. Further functional experiments showed that LINC00958 sponged miR-3619-5p to promote HCC progression. Previous studies indicated that miR-3619-5p inhibits cell proliferation and migration in HCC [
34]. miR-3619-5p is involved in LINC00202-mediated retinoblastoma progression through targeting the expression of an oncogene RIN1 [
35]. miR-3619-5p has also been demonstrated to exert a tumor-suppressive role in several types of malignancies, including bladder cancer [
36], lung cancer [
37], prostate cancer [
38], and cutaneous squamous cell carcinoma [
39].
To investigate the target gene of the LINC00958/miR-3619-5p pathway in HCC, we combined four bioinformatics algorithms and RNA sequencing results and found that HDGF was the downstream effector of the LINC00958/miR-3619-5p axis. HDGF has been established as an oncogene that facilitates the progression of HCC [
40,
41]. One recent study suggested that HDGF could affect lipid metabolism via SREBP1 in HCC [
25]. Our results revealed that LINC00958 facilitated lipogenesis via the miR-3619-5p/HDGF pathway. LINC00958 increased cellular cholesterol and triglyceride levels and contributed to lipid droplet formation. Key enzymes in lipogenesis, including SREBP1, FASN, SCD1, and ACC1, were also affected by LINC00958. As one of the hallmarks of cancer, metabolic alteration plays an indispensable role in cancer. However, only a few studies focused on the involvement of lncRNAs in HCC lipid metabolic reprogramming. Our data have provided novel insights into the lipogenesis-modulating role of LINC00958 in HCC.
Recent years have witnessed remarkable advancements of m
6A modification in regulating all stages of the RNA life cycle. The deposition of m
6A is encoded by “writers” that catalyze m
6A formation (such as METTL3, METTL14, and WTAP), “erasers” that selectively remove the m
6A code (such as FTO and ALKBH5), and “readers” that decode m
6A methylation (such as YTH domain proteins and IGF2BP) [
42]. m
6A has been demonstrated to affect the targeted mRNA or miRNA and participate in the progression of various cancers [
43]. However, studies on m
6A modification in lncRNAs are scarce in the field of cancer. Recently, Wu et al. demonstrated that m
6A modification upregulates lncRNA RP11 by increasing its nuclear accumulation [
27]. m
6A was suggested to be highly enriched on lncRNA FAM225A and can increase its RNA stability [
26]. Herein, we revealed that m
6A methylation was enriched within LINC00958 in HCC cells using both in silico data and m
6A RIP experiment. Moreover, METTL3 regulated the m
6A modification in LINC00958, thus affecting its RNA stability. These results suggested that elevation of LINC00958 in HCC may be attributed to the m
6A modification.
Targeting delivery of siRNA using NPs has been recognized as practical and promising for cancer nanotherapy. Liposomes and viral vectors have been implicated to be potential vehicles for siRNA delivery, but they may induce toxicity and cannot maintain sustained release of siRNAs [
16]. Approved by the Food and Drug Administration, PLGA is biodegradable and non-toxic and provides high stability, prolonged blood circulation time, and sustained release profile [
44]. PLGA has gained substantial attention among the various polymers developed for formulation of nanoplatform and has been used for siRNA delivery. Byeon et al. used PLGA-based NPs incorporating FAK siRNA for overcoming chemoresistance in ovarian cancer [
45]. PLGA NPs loaded with siRNA against osteopontin have been demonstrated to be effective for mammary carcinoma systemic treatment [
46]. PEGylated NPs are regarded as “stealth NPs” and characterized by increased circulation time in vivo and tumor uptake. The surface shielding with PEG avoids plasma protein adsorption, protects NPs from the immune recognition, and increases bioavailability [
18].
In this study, we developed and characterized a PEGylated PLGA nanoplatform loaded with LINC00958 siRNA for HCC therapy. PLGA-based nanosystem ensured the controlled release of si-LINC00958 and protected it from premature degradation. According to the results from cellular uptake experiments, NPs exhibited enhanced uptake into the tumor cells, which may facilitate the accumulation of NPs in the tumor. Biodistribution of NPs by systemic administration showed accumulated NPs in the xenograft tumor sites as well as the liver. The enhanced permeability and retention (EPR) effect is based on the leaky vasculature and poor lymphatic drainage present in the tumor. NPs > 100 nm can avoid being engulfed by the mononuclear phagocyte system and excreted by the kidney, while NPs < 400 nm preferentially accumulate in tumor sites and exhibit an optimal EPR effect [
47]. Taking advantage of the EPR effect, PLGA-PEG(si-LINC00958) NPs achieved high concentration in HCC xenografts in vivo. Since the liver is the primary organ responsible for drug biotransformation, many NP-based drug delivery systems present substantial amounts of NPs in the liver [
48,
49]. The results from PDX models demonstrated that this nanodrug system prominently reduced tumor burden. Compared with the control group, hampered tumor growth was observed in the PLGA-PEG(si-LINC00958) NP group. In addition, the results from H&E histopathological analysis and blood biochemical examination confirmed no significant toxic side effects.
Conclusions
In summary, we comprehensively investigated the functional roles, molecular mechanisms, and clinical applications of LINC00958 in HCC. Our results revealed that LINC00958 was upregulated in HCC cell lines and tissues. High LINC00958 expression level was an independent prognostic factor for overall survival in HCC patients. We showed that LINC00958 promoted HCC cell proliferation, migration, invasion, and lipogenesis through the miR-3619-5p/HDGF axis. Moreover, PDX models were employed to confirm the effects of LINC00958 on HCC growth in vivo. We demonstrated that m6A modification was responsible for the upregulation of LINC00958 in HCC. For potential clinical application, we developed a novel nanoplatform encapsulating LINC00958 siRNA for HCC systemic treatment. Our study revealed that LINC00958 plays a crucial part in HCC lipogenesis and progression and highlighted its value as a prognostic predictor and nanotherapeutic candidate in HCC.
Acknowledgements
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.